Influenza A (H1N1) Swine Flu – Update Fifteen
Influenza A (H1N1) Swine Flu – Update Fifteen
1pm Friday 1 May 2009
Please
attribute to Dr Mark Jacobs, Director of Public
Health
The WHO now refers to the new influenza virus as Influenza A (H1N1).
New Zealand numbers
This morning's
situation report shows there are 13 probable cases and 3
confirmed cases of Influenza A (H1N1) Swine Flu.
In addition there are 136 suspected cases. These are people who have developed symptoms of influenza within seven days of having been in the areas of concern or are close contacts of cases and have symptoms.
In total there are 401 people in isolation and being treated with Tamiflu. This includes suspected cases and people without symptoms who are being isolated as a precaution because they are in close contact with a suspected case.
These numbers will fluctuate as a result of more suspected cases being found, or suspected cases being ruled out.
International situation
http://www.who.int/en/
As at 9am Friday 1 May 11
countries have officially reported 257 cases of Influenza A
(H1N1) Swine Flu infection.
The United States Government
has reported 109 laboratory confirmed human cases, including
one death. Mexico has reported 97 confirmed human cases of
infection, including seven deaths.
The following
countries have reported laboratory confirmed cases with no
deaths - Austria (1), Canada (19), Germany (3), Israel (2),
Netherlands (1), New Zealand (3), Spain (13), Switzerland
(1) and the United Kingdom (8).
Tamiflu for normal
seasonal influenza
The current stock of Tamiflu is
sufficient to provide cover for 30 percent of the
population. An additional 125,000 doses of the antivral
drug Relenza have been ordered. Once filled, this will
increase the national stock of antiviral drugs by 10 per
cent.
No changes to the controls allowing access to Tamiflu are likely in the short term. The Medicines Classification Committee (MCC) which in 2006 recommended that pharmacists be allowed to sell Tamiflu, required direct consultation in order to ensure the product was only being supplied to patients with influenza.
The controls on supply were placed in order to minimise the risk of inappropriate use to treat other viral infections, reduce the risk of development of resistance to Tamiflu and ensure the product was not being sold for use in children under 12 years of age. In addition, the MCC were concerned that unless sale to a patient in the pharmacy was required, the risk of the NZ product being purchased from pharmacists by overseas consumers via the internet, thereby depriving NZ of supplies of Tamiflu, would be unacceptably high. This risk of diversion of supply is especially high during times when there’s heightened public concern about influenza.
The MCC further considered the requirement for face-to-face consultation to obtain Tamiflu at its meeting in June 2008 and confirmed its earlier position that until more data was available on use in pharmacy and the factors leading to resistance became clearer, the requirement will remain in place.
Seasonal influenza vaccine
There has been a
significant increase in demand for the seasonal influenza
vaccine in New Zealand in the past three days. We are
increasing the national stock of seasonal influenza vaccine
by 125,000 doses. This is in addition to the 800,000 doses
already in stock. Last year the country used 760,000 doses
of seasonal influenza vaccine. The influenza vaccine season
runs until the end of June.
•60,000 doses left (from
120,000 available last week).
•Demand usually slows
down this time as ‘all at risk’ are usually
vaccinated.
•Pharmac cannot predict demand which
should be dying off now but last
week demand
was twice normal.
Alert levels
The World Health
Organisation current level of influenza pandemic alert
remains at five.
Phase 5 is characterized by human-to-human spread of the virus into at least two countries in one WHO region. While most countries will not be affected at this stage, the declaration of Phase 5 is a strong signal that a pandemic is imminent and that the time to finalize the organization, communication, and implementation of the planned mitigation measures is short.
New Zealand's status is Code Yellow. We are
currently in Phase 5.1. New Zealand is not escalating its
plan at the moment. Our actions are to limit any spread of
Influenza A (H1N1) Swine Flu that has come to New Zealand.
We have taken a precautionary approach from the
start.
More information on New Zealand's pandemic plan can be accessed on the Ministry of Health website www.moh.govt.nz

Click for big version
Definitions
Suspected is
all people who display flu symptoms AND have travelled
through areas of concern, or are close contacts of
cases.
Probable are all suspected cases that test
positive for Influenza A – all these cases are being
treated as confirmed for the purposes of
treatment.
Isolation includes all cases and contacts in
isolation or quarantine (do not include hospital isolation).
This includes many people without symptoms who are being
isolated as a precaution because they are in close contact
with a suspected case.
Healthline 0800 611 116